key: cord-0867446-puxi2t5s
authors: Tang, Keyun; Wang, Yuanzhuo; Zhang, Hanlin; Zheng, Qingyue; Fang, Rouyu; Sun, Qiuning
title: Cutaneous manifestations of the Coronavirus Disease 2019 (COVID‐19): A brief review
date: 2020-05-22
journal: Dermatol Ther
DOI: 10.1111/dth.13528
sha: 8282c1b73ddeb8ed1c75fccfd5f732ef92307247
doc_id: 867446
cord_uid: puxi2t5s

COVID‐19, first appeared in December 2019 in Wuhan, China, has been spreading quickly throughout the world. We reviewed the evidence on cutaneous manifestations of COVID‐19 based on PubMed database. The searching strategy was (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. After independent review by two authors, 14 studies with 228 confirmed cases were included in the analysis. A total of 60 patients developed skin rashes, and the age ranged from 8 to 84. Exanthematous eruptions potentially related to COVID‐19 infection were highly variable and heterogeneous. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox‐like or varicelliform). Petechiae rash, livedo reticularis, and reactivation of oral HSV‐1 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis‐like) skin lesions caused concern among dermatologists. Exanthems were widely distributed and were primarily located on the trunk. Associated symptoms, latency time, treatment, and prognosis were also carefully summarized. This study reviewed the recently published COVID‐19 studies with skin manifestations, which may pave the way for further research.

of cutaneous manifestations associated with COVID-19 were included in this review.

Overall, 16 studies with 256 confirmed COVID-19 cases were included in the final analysis. A total of 88 patients developed skin rashes, and the age ranged from 8 to 84. Of the 50 patients with determined gender, 27 (54%) were males and 23 (46%) were females.

The only prospective study showed that 5 (4.9%) patients in France presented with cutaneous manifestations associated with infections, 2 which was lower than the rate of occurrences of skin rashes in a previous retrospective study (20.4%, 18 out of 88; Table 1 ). 3 Exanthematous eruptions potentially related to COVID-19 infection were highly variable. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox-like or varicelliform). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Petechiae rash, 13 livedo reticularis, 14 and reactivation of oral herpes simplex virus type 1 (HSV-1) 2 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis-like) skin lesions caused concern among dermatologists. 15, 16 Exanthems were widely distributed and were primarily located on the trunk.

Patients often presented with other clinical symptoms during the disease course, including fever, cough, headache, weakness, coryza, dyspnea, and other respiratory problems. 1, 5, [7] [8] [9] [10] [11] [12] [13] [14] The latency time from systemic symptoms to exanthem ranged from −2 to 21 days, and lesions of three patients were detected during the prodromal or subclinical phase. 1, 8, 11 Thirteen patients remained asymptomatic across the entire observation period except for peculiar lesions, red-purple papules, and additional erythematous. 4, 16 Of the nine patients receiving medications, four patients received conservative drug therapy for exanthem. 1, 5, 6, 9 Oral antihistamines contributed to clinical and symptomatic improvement in two patients with urticaria. 1, 6 Local corticosteroids were given to a patient with erythematous-yellowish papules, however, these papules progressed into hardened and pruritic erythematous plaque 3 days later despite the treatment. 5 Another patient with confluent erythematous patches and worsening dermatitis demonstrated a good response to triamcinolone 0.1% cream. 9 These agents were used in combination with systemic drugs for infectious complications and symptoms. Five patients receiving treatment for symptoms of COVID-19 infection had no specific agents for skin rashes. Based on the recorded clinical outcomes in four of five patients, rash improved or disappeared within a few days spontaneously. 10, 11 Among nine patients receiving treatments, 1, [5] [6] [7] [9] [10] [11] two presented with rash before 1,11 while six developed skin eruptions following drug administration. 5-7,10,11

Recently, Recalcati and colleagues reported the cutaneous manifestations of COVID-19 infection in Italy and asked for more papers to confirm and better understand the pattern of skin involvement with COVID-19. 3 As the disease became pandemic globally, additional evidence has been constantly emerging. Therefore, we conducted a study to briefly review the ongoing research advances.

For COVID-19 treatment, one possible treatment option was the combination of anti-viral medicine (hydroxychloroquine and lopinavir/ ritonavir) with antibiotics (azithromycin, levofloxacin, and ceftriaxone).

Supporting therapy of paracetamol or benzonatate could also be performed. However, only four case reports mentioned medicine usage for skin symptoms, including oral antihistamines and local corticosteroids. 1, 5, 6, 9 Antihistamines and corticosteroids are commonly used as anti-inflammation and anti-allergic agents, but they will increase the risk of infection as well. This paradox may restrict the usage of these 

Urticarial eruption in COVID-19 infection

Comment on "cutaneous manifestations in COVID-19: a first perspective " by Recalcati S

Cutaneous manifestations in COVID-19: a first perspective

A Case of COVID-19 Presenting in Clinical Picture Resembling Chilblains Disease. First report from the Middle East

Cutaneous manifestations in COVID-19: a new contribution

Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies

Reply to "COVID-19 can present with a rash and be mistaken for dengue": petechial rash in a patient with COVID-19 infection

Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients

Morbilliform Exanthem associated with COVID-19. JAAD Case Rep

A distinctive skin rash associated with coronavirus disease 2019 ?

Cutaneous Clinico-pathological findings in three COVID-19-positive patients observed in the metropolitan area of

Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: a diagnostic clue? Pediatr Dermatol

COVID-19 can present with a rash and be mistaken for dengue

A dermatologic manifestation of COVID-19: transient Livedo Reticularis

Vascular skin symptoms in COVID-19: a french observational study. J Eur Acad Dermatol Venereol

Acral cutaneous lesions in the time of COVID-19

Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): A brief review

The authors have no conflict of interest to declare.

All authors contributed to the manuscript. Keyun Tang